Moreover, cell viability assays, carried out with both human melanoma cell lines, revealed that combination therapy using AdV-D24-ICOSL-CD40L with pembrolizumab led to higher anti-cancer activity compared to the other tested groups. Here, CD40LG is linked to melanoma.